Therapeutic Adalimumab antibody from the original Humira® and biosimilar commercial drugs.
Product batch
| Expiry date
| Brand & Origin
| Price
| 1. Select quantity range | 2. Your quantity | |
|---|---|---|---|---|---|---|
2025.05 |
Humira® DE |
112,50 €
/mg
|
mg |
|||
2018.09 |
Humira® DE |
113,00 €
/mg
|
Select quantity:
|
mg |
||
2018.12 |
Humira® LV |
113,00 €
/mg
|
Select quantity:
|
mg |
||
2019.03 |
Humira® DE |
113,00 €
/mg
|
Select quantity:
|
mg |
||
2019.03 |
Humira® DE |
113,00 €
/mg
|
Select quantity:
|
mg |
||
2019.07 |
Humira® LV |
113,00 €
/mg
|
Select quantity:
|
mg |
Product batch
| Expiry date
| Brand & Origin
| Price
| 1. Select quantity range | 2. Your quantity | |
|---|---|---|---|---|---|---|
2021.12 |
Amgevita® DE |
152,00 €
/mg
|
Select quantity:
|
mg |
||
2023.02 |
Hulio® DE |
152,00 €
/mg
|
Select quantity:
|
mg |
||
2023.10 |
Hukyndra® DE |
152,00 €
/mg
|
Select quantity:
|
mg |
||
2024.02 |
Yuflyma® DE |
354,00 €
/mg
|
Select quantity:
|
mg |
||
2024.02 |
Yuflyma® DE |
88,50 €
/mg
|
Select quantity:
|
mg |
||
2023.10 |
Idacio® DE |
177,50 €
/mg
|
Select quantity:
|
mg |
||
2023.10 |
Imraldi® DE |
152,00 €
/mg
|
Select quantity:
|
mg |
||
2024.06 |
Hyrimoz® DE |
152,00 €
/mg
|
Select quantity:
|
mg |
Evidentic’s analytical service includes a comprehensive array of methods to support the drug development process, including, for example, structure, aggregation, degree of isomerization and N-glycans identification of the active pharmaceutical ingredient (API).
Here you will find the product information for the reference product.
| Drug name | Humira® |
| INN | Adalimumab |
| API type | Adalimumab is a recombinant human monoclonal antibody expressed in Chinese Hamster Ovary cells. |
| Pharmacotherapeutic group | Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors. |
| ATC code | L04AB04 |
| Target of antibody | TNF alpha |
| General function | Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of0.1-0.2 nM). |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM). |
| Original license holder | AbbVie Biotechnology GmbH Knollstrasse 67061 Ludwigshafen Germany |
| Marketing authorisation numbers | EU/1/03/256/022 |
| Marketing authorisation holder | AbbVie Ltd Maidenhead SL6 4UB United Kingdom |
| Name of the manufacturer of the biological active substance | AbbVie Bioresearch Center 100 Research Drive Worcester MA 01605 USA |
| Name and address of the manufacturer(s) responsible for batch release | AbbVie Biotechnology GmbH Knollstrasse 67061 Ludwigshafen Germany |
| Max shelf life | 24 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Mannitol Polysorbate 80 |
Do you have any questions about the product, the ordering process or any other detail? Please contact us, we will reply within 24 hours.
At Evidentic, we deal with clinical-grade therapeutic molecules. Think of them as the building blocks for tomorrow’s groundbreaking treatments. These molecules are the active ingredients you’ll find in original drugs prescribed to patients, produced under the strictest quality and safety standards. They’ve also been therapeutically proven through rigorous clinical trials, meaning their effectiveness and safety for treating human diseases have been established. By offering researchers access to these essential tools, we’re fueling the fight for a healthier future.
Unlike some commercially available molecules, Evidentic’s clinical-grade therapeutics aren’t just research possibilities – they’re proven powerhouses! Derived from actual drugs used to treat human diseases, these molecules have already undergone rigorous testing and met the strictest safety and quality standards. This means researchers can focus their energy on groundbreaking discoveries, not questioning the reliability of their tools. With Evidentic, you get the confidence of knowing you’re working with the building blocks for real-world medical advancements.
If you struggle to source clinical-grade biologics you need for your research, Evidentic bridges the gap. We offer royalty-free research consumables (RUO-only) derived from original licensed drugs, giving you access to these critical research tools without the hassle.
But that’s not all. We understand the importance of batch variety in your research. That’s why we’ve built a comprehensive stock library, offering numerous batches of the same active pharmaceutical ingredient (API). This dedication to choice means you can find the exact batch that aligns with your specific research needs.
And because we’re constantly expanding our library, you can be sure we’re actively searching for new batches to add to your research arsenal. With Evidentic, unlock the power of readily available, high-quality research tools and accelerate your scientific breakthroughs.
Evidentic offers access to pharmaceuticals approved by the U.S. FDA (Food and Drug Administration) and/or the EMA (European Medicines Agency). This gives you access to a wider variety of molecules for your research, potentially shortening timelines and boosting the accuracy of your results. Compare EU and US molecules head-to-head, and accelerate your early drug development projects with access to these high-quality research tools. Contact us today to explore the possibilities!
Evidentic’s aliquots from approved pharnaceuticals can be used for analytical, in vitro research, typically executed in early drug development stage of drug discovery programs, like:
